Company Description

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.

The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.

It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.

The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.

Enveric Biosciences, Inc.

Country	United States
Founded	1994
Industry	Biotechnology
Sector	Healthcare
Employees	6
CEO	Joseph Tucker

Contact Details

Address: 245 First Street, Riverview II Cambridge, Massachusetts 02142 United States
Website	enveric.com

Stock Details

Ticker Symbol	ENVB
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	890821
CUSIP Number	29405E505
ISIN Number	US29405E5050
Employer ID	95-4484725
SIC Code	2834

Key Executives

Name	Position
Dr. Joseph Edward Tucker Ph.D.	Chief Executive Officer and Director
Dr. Peter J. Facchini Ph.D.	Chief Innovation Officer

Latest SEC Filings

Date	Type	Title
Feb 18, 2026	424B3	Prospectus
Feb 17, 2026	EFFECT	Notice of Effectiveness
Feb 11, 2026	D	Notice of Exempt Offering of Securities
Feb 10, 2026	S-1	General form for registration of securities under the Securities Act of 1933
Feb 6, 2026	8-K	Current Report
Feb 6, 2026	424B5	Filing
Feb 4, 2026	SCHEDULE 13G	Filing
Feb 2, 2026	SCHEDULE 13G	Filing
Jan 28, 2026	8-K	Current Report
Jan 28, 2026	424B5	Filing

View All SEC Filings